Compass Pathways stock crumbled Tuesday despite seemingly positive test results for its psychedelic drug in treatment-resistant depression.

Compass Pathways plc CMPS on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the ...

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.

Introduction The Jeep Compass Still Trails the Best Compact SUVs Jeep’s small SUV has a peppy engine and an attractive interior, but it can’t overcome numerous flaws Overview.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...

The footnote should read that we're dealing with a range figure according to the permissive WLTP standard, whereas the EPA would surely reduce that count ...